Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can ...

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

Panelist discusses how the MonumenTAL-1 study led to the approval of talquetamab in patients with 4 or more prior lines of ...

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS ...

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...

Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...

Panelist discusses how talquetamab’s step-up dosing strategy aims to mitigate cytokine release syndrome, a common immunologic toxicity. The reported grade 1 CRS with altered taste and dry mouth ...

A study of 9,146 patients found no OS difference among first-line CDK4/6 inhibitor combinations for HR+/HER2- metastatic ...

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...